Mirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Jun 2021 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 LUCENT 2 trial in moderate-to-severe ulcerative colitis in Jun 2023; Primary completion and completion of P3 LUCENT 3 trial (NCT03519945) in moderate-to-severe ulcerative colitis in Aug 2023
Trial completion date • Trial primary completion date • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|